Prima BioMed announces CVac trial results

THE ROADHOUSE PHARMACY: Prima BioMed (ASX: PRR) has claimed CVac has demonstrated a positive trend in overall survival (OS) over standard of care in second remission ovarian cancer patients in the CAN-003 protocol.

Dr. Heidi Gray, the trial’s lead investigator, presented these findings at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago recently.

Prima BioMed described Dr. Gray’s presentation saying it highlighted that in the second remission patient population, the median overall survival of the control group was approximately 26 months, consistent with previous industry trials, while the CVac treated group is surviving for significantly longer.

The company went on to say that after 30 months of observation, the CVac group is not yet close to reaching a median survival estimate, which requires half of the patients to have deceased.

“While it is too early to make a final analysis, indications in the overall survival benefits of CVac in second remission ovarian cancer patients is extremely encouraging,” Prima BioMed CEO Matthew Lehman said in the company’s announcement to the Australian Securities Exchange.

“Following the release of the final PFS data last month, this further validates our much larger, 210-patient phase 2 CAN-004-B trial which has OS as the primary endpoint and PFS as a secondary endpoint.

“We look forward to reporting on the final OS data towards the end of this calendar year.”

In second remission patients (n=20) from CAN-003, median OS for control group patients was 26.25 months while a median for CVac patients was not yet reached after 30 months (hazard ratio=0.17; p=0.07).

Medians for the control group and CVac treated patients have not yet been reached for first remission patients.

Dr. Gray’s presentation also included the final PFS data at ASCO for CAN-003.

As previously announced, in second remission patients (n=20) from CAN-003, median PFS for CVac was estimated to be greater than 12.91 months, compared to median PFS of 4.94 months for the control group (hazard ratio=0.32; p=0.04).

Website: www.primabiomed.com.au